Last reviewed · How we verify
radioligand [11C]raclopride
radioligand [11C]raclopride is a Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development.
At a glance
| Generic name | radioligand [11C]raclopride |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- radioligand [11C]raclopride CI brief — competitive landscape report
- radioligand [11C]raclopride updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about radioligand [11C]raclopride
What is radioligand [11C]raclopride?
radioligand [11C]raclopride is a Small molecule drug developed by AstraZeneca.
Who makes radioligand [11C]raclopride?
radioligand [11C]raclopride is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).
What development phase is radioligand [11C]raclopride in?
radioligand [11C]raclopride is in Phase 1.
Related
- Manufacturer: AstraZeneca — full pipeline
- Compare: radioligand [11C]raclopride vs similar drugs
- Pricing: radioligand [11C]raclopride cost, discount & access